ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Dexamethasone

Also written as “dexamethasone”, “OTO-104” and “Dexycu”.

Its studies are mostly in Multiple Myeloma · Cataract · Macular Edema · Meniere Disease · Conjunctivitis, Allergic, led by 30 companies.

Drug pageDexamethasone: every studyMany companies study it; this page follows only the 92 they lead. All 1,797 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 6, 200392 company-led studies, 7 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only200 open or runningphase 3since Mar 6, 2003Mar 6, 2003none ahead
Ocular Therapeutixits history only100 open or runningphase 3since Jan 9, 2014Jan 9, 2014none ahead
Takedaits history only100 open or runningphase 4since May 30, 2017Jul 25, 2007none ahead
Oculisits history only50 open or runningphase 3since Sep 2, 2021Oct 16, 2019none ahead
Sun Pharmaceutical Industriesits history only50 open or runningphase 3since Dec 19, 2007Dec 19, 2007none ahead
Oncotherapeuticsits history only40 open or runningphase 2since Aug 26, 2008Aug 26, 2008none ahead
EyePoint Pharmaceuticalsits history only30 open or runningphase 4since Dec 13, 2021Dec 13, 2021none ahead
Hamad Medicalits history only32 open or runningphase 3since Nov 30, 2020Jan 12, 2010none ahead
Sanofiits history only33 open or runningphase 2since Oct 20, 2020Oct 20, 2020Apr 1, 2027phase 2 · NCT06356571
Alconits history only20 open or runningphase 4since Feb 29, 2008Feb 29, 2008none ahead

Also a collaborator on its studies: Karyopharm Therapeutics, AbbVie, Onyx Therapeutics, Abbott, Tigermed Consulting, Accelovance, ORA, Johnson & Johnson, Hoffmann-La Roche, Amgen, Novum Pharmaceutical Research Services, Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jan 5, 2011.

  1. Jun 1, 2021Early phase 1 study in HealthyOcular Therapeutix · NCT04945824 · 2 enrolled · United States
  2. Sep 2, 2021Phase 3 study in Diabetic Macular EdemaOculis · NCT05066997 · 552 enrolled · United States, Hong Kong, India and more
  3. Nov 24, 2021Phase 3 study in Inflammation Eye PainOculis · NCT05147233 · 241 enrolled · United States
  4. Dec 13, 2021EyePoint Pharmaceuticals’ first study: phase 4 study in CataractNew to EyePoint PharmaceuticalsEyePoint Pharmaceuticals · NCT05191706 · 17 enrolled · United States
  5. Sep 16, 20222 phase 3 studies in CataractEyePoint Pharmaceuticals · NCT05550363, NCT05550350
  6. Jan 20, 2023Phase 2 study in Multiple MyelomaSanofi · NCT05704049 · 118 enrolled · Australia, Brazil, China and more
  7. Aug 6, 2023Named dexamethasoneINNProposed as its International Nonproprietary Name in WHO's List 129 · before, OTO-104
  8. Nov 7, 2023Phase 3 study in Inflammation Eye PainOculis · NCT06128369 · 117 enrolled · United States
  9. Dec 7, 2023Phase 3 study in Diabetic Macular EdemaOculis · NCT06172257 · 401 enrolled · United States, Argentina, India and more
  10. Apr 5, 2024Phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571 · 64 enrolled · United States
  11. May 11, 2024Ocumension Therapeutics (Shanghai)’s first study: phase 3 study in InflammationNew to Ocumension Therapeutics (Shanghai)Ocumension Therapeutics (Shanghai) · NCT06429306 · 285 enrolled · China
  12. Jun 20, 2024Phase 4 study in InflammationOcumension Therapeutics (Shanghai) · NCT06497699 · 263 enrolled · China
  13. Sep 12, 2024Cochlear’s first study: no phase study in Hearing LossNew to CochlearCochlear · NCT06598059 · 56 enrolled · United States
  14. Jul 30, 2025Laboratorios Sophia S.A de C.V.’s first study: phase 3 study in Cataract ExtractionNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT07305987 · 134 planned · Mexico
  15. Oct 26, 2026Primary completion moved from 2027-01-08 to 2027-04-01Date moved laterphase 2 · +3 months · NCT06356571

Ahead

  1. Apr 1, 2027Primary completion: phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571
  2. Sep 13, 2027Primary completion: phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT04643002

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
TriamcinoloneruleResearch Insightphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The newest 60 of 92 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07305987Cataract Extraction · Mexico3RecruitingLaboratorios Sophia S.A de C.V.Jun 30, 2026134
NCT06598059Hearing Loss · United States–Active, not recruitingCochlearFeb 2, 202656
NCT06497699Inflammation · China4CompletedOcumension Therapeutics (Shanghai)Jul 8, 2023263
NCT06429306Inflammation · China3CompletedOcumension Therapeutics (Shanghai)Nov 24, 2023285
NCT06356571Plasma Cell Myeloma Refractory · United States2Active, not recruitingSanofiApr 1, 202764
NCT06172257Diabetic Macular Edema · United States, Argentina, India and more3CompletedOculisApr 2, 2026401
NCT06128369Inflammation Eye Pain · United States3TerminatedOculisMay 2, 2024117
NCT05704049Multiple Myeloma · Australia, Brazil, China and more2Active, not recruitingSanofiDec 22, 2025118
NCT05550363Cataract3WithdrawnEyePoint PharmaceuticalsSep 20230
NCT05550350Cataract3WithdrawnEyePoint PharmaceuticalsSep 20230
NCT05191706Cataract · United States4TerminatedEyePoint PharmaceuticalsAug 22, 202517
NCT05147233Inflammation Eye Pain · United States3CompletedOculisJun 22, 2023241
NCT05066997Diabetic Macular Edema · United States, Hong Kong, India and more3CompletedOculisApr 10, 2026552
NCT04945824Healthy · United StatesEarly 1TerminatedOcular TherapeutixNov 1, 20222
NCT04911361Dry Eye Syndromes · United States4CompletedResearch InsightDec 28, 202150
NCT04654507Glomerulonephritis · Qatar3RecruitingHamad MedicalDec 2023120
NCT04643002Plasma Cell Myeloma Refractory · United States, Australia, France and more2RecruitingSanofiSep 13, 2027258
NCT04711213Cataract in Inflammatory Ocular Disorders · El Salvador2CompletediDropOct 31, 202060
NCT04539548Cataract · United States3CompletedOcular TherapeutixDec 21, 202365
NCT04130802Keratitis · United States2CompletedOculisJan 31, 2020153
NCT04050865Conjunctivitis, Allergic · United States3CompletedOcular TherapeutixFeb 28, 202096
NCT03739528Cataract · Italy3CompletedNTC srlDec 19, 2018808
NCT03740659Cataract · Italy2CompletedNTC srlDec 6, 2018125
NCT03687931Endophthalmitis · United States2CompletediDropFeb 28, 201960
NCT03646916Diabetes Mellitus · United States4WithdrawnAscension HealthDec 31, 20200
NCT03651128Multiple Myeloma · United States, Belgium, Canada and more3CompletedBristol-Myers SquibbApr 13, 2026386
NCT03608501Multiple Myeloma · Brazil2WithdrawnTakedaJun 30, 20210
NCT03523221Anaphylaxis · Qatar1RecruitingHamad MedicalDec 2024210
NCT03439293Multiple Myeloma · United States, Czechia, France and more2CompletedTakedaJan 1, 202261
NCT03416374Relapsed and/or Refractory Multiple Myeloma · Japan4CompletedTakedaMay 28, 202145
NCT03192150Inflammation · United States3CompletedSun Pharmaceutical IndustriesNov 18, 2019246
NCT03192137Inflammation · United States3CompletedSun Pharmaceutical IndustriesApr 17, 2019260
NCT03173092Multiple Myeloma · United States4TerminatedTakedaMar 30, 2026141
NCT03104270Multiple Myeloma · United States2TerminatedOncotherapeuticsOct 25, 201913
NCT03033316Multiple Myeloma2TerminatedEnceladus Pharmaceuticals BVAug 20207
NCT02988882Chronic Allergic Conjunctivitis3CompletedOcular TherapeutixApr 27, 201686
NCT02916420Multiple Myeloma · China3UNKNOWNSimcere Pharmaceutical GroupJun 201873
NCT02917941Relapsed and/or Refractory Multiple Myeloma · Japan2CompletedTakedaAug 31, 201934
NCT02736175Post-Surgical Ocular Pain3CompletedOcular TherapeutixMay 2016438
NCT02547623Cataract · United States3CompletedICON BioscienceAug 16, 2016194
NCT02468700Dry Eye Syndromes2CompletedOcular TherapeutixAug 201543
NCT02445326Chronic Allergic Conjunctivitis3CompletedOcular TherapeutixAug 201573
NCT02348528Multiple Myeloma · China2CompletedBristol-Myers SquibbSep 29, 201665
NCT02206425Multiple Myeloma · United States2CompletedOncotherapeuticsJan 19, 201845
NCT02089113Post-Surgical Ocular Pain3CompletedOcular TherapeutixJan 2015241
NCT02062905Chronic Allergic Conjunctivitis2CompletedOcular TherapeutixAug 201468
NCT02034019Pain · United States3CompletedOcular TherapeutixDec 2014247
NCT02045017Multiple Myeloma · Austria, France, Germany and more2CompletedBristol-Myers SquibbJan 27, 201781
NCT02011113Multiple Myeloma · Japan2CompletedBristol-Myers SquibbSep 201436
NCT01946477Multiple Myeloma · United States, Canada, Japan and more2CompletedBristol-Myers SquibbApr 30, 2025186
NCT01910155Otitis Externa · United States, Puerto Rico3TerminatedPar HealthFeb 2015455
NCT01891643Newly Diagnosed, Previously Untreated Multiple Myeloma · United States, Greece, Italy and more3TerminatedBristol-Myers SquibbJun 25, 202023
NCT01792102Multiple Myeloma · United States2UNKNOWNOncotherapeuticsDec 201838
NCT01698801Multiple Myeloma · Japan2CompletedBristol-Myers SquibbNov 26, 201326
NCT01660750Multiple Myeloma · United States1CompletedCriteriumAug 201529
NCT01593410Multiple Myeloma · China2CompletedBristol-Myers SquibbJan 3, 2013194
NCT01575925Multiple Myeloma · United States, Canada1CompletedBristol-Myers SquibbAug 7, 201825
NCT01543490Motor Activity · United States3CompletedSun Pharmaceutical IndustriesFeb 4, 2020558
NCT01328236Leukemia, Plasma Cell · China2UNKNOWNClinical Service, ChinaSep 201320
NCT01277289Crohn Disease · Italy, Romania, Spain3TerminatedQuince TherapeuticsDec 30, 201151

How it is read

Names in the registry

  • “Dexamethasone”, 94 entries
  • “dexamethasone”, 20 entries
  • “OTO-104”, 9 entries
  • “Dexycu”, 4 entries
  • “Dexamethasone Oral”, 3 entries

Codes read as this program: OCS01.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.